zl1201
mAbexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Apr 30, 2020 (NCT04257617)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Leukocyte surface antigen CD47INHIBITOR
CD47 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04257617 | Phase 1 | Apr 30, 2020 | Mayo Clinic, PPD, Zai Lab Pty. Ltd. |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Mayo Clinic | Academic/Hospital | 1 | 0 | 1 | 2020 |
| PPD | For profit | 1 | 0 | 1 | 2020 |
| Zai Lab Pty. Ltd. | For profit | 1 | 1 | 1 | 2020 |
3 organizations
Page 1 / 1